{"filing":{"accession_number":"0001171843-26-006788","cik":"0001828253","ticker":"EVAX","company_name":"Evaxion A/S","form":"6-K","filing_date":"2026-10-23","report_date":"2026-10-23","primary_document":"f6k_102226.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1828253/000117184326006788/f6k_102226.htm"},"events":[{"id":37380,"run_id":34458,"accession_number":"0001171843-26-006788","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces positive three-year clinical trial data for EVX-01, Evaxion's lead personalized cancer vaccine candidate, showing 89% vaccine target precision, sustained T-cell responses, and durable clinical responses in advanced melanoma patients. While the disclosure reports clinical trial results rather than financial results or a discrete corporate event, it represents a material operational milestone for a clinical-stage biotech company—the data supports advancement of the company's lead asset and validates its AI-Immunology platform technology. This is neither a periodic financial report nor a traditional earnings release, but rather a material clinical/operational development that would affect investor assessment of the company's pipeline and technology platform.","company_name":"Evaxion A/S","ticker":"EVAX","filing_date":"2026-10-23","form":"6-K","submitted_at":null,"items":[{"id":42075,"accession_number":"0001171843-26-006788","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces positive three-year clinical trial data for EVX-01, Evaxion's lead personalized cancer vaccine candidate, showing 89% vaccine target precision, sustained T-cell responses, and durable clinical responses in advanced melanoma patients. While the disclosure reports clinical trial results rather than financial results or a discrete corporate event, it represents a material operational milestone for a clinical-stage biotech company—the data supports advancement of the company's lead asset and validates its AI-Immunology platform technology. This is neither a periodic financial report nor a traditional earnings release, but rather a material clinical/operational development that would affect investor assessment of the company's pipeline and technology platform.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-23T10:04:22.479606+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42075,"accession_number":"0001171843-26-006788","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces positive three-year clinical trial data for EVX-01, Evaxion's lead personalized cancer vaccine candidate, showing 89% vaccine target precision, sustained T-cell responses, and durable clinical responses in advanced melanoma patients. While the disclosure reports clinical trial results rather than financial results or a discrete corporate event, it represents a material operational milestone for a clinical-stage biotech company—the data supports advancement of the company's lead asset and validates its AI-Immunology platform technology. This is neither a periodic financial report nor a traditional earnings release, but rather a material clinical/operational development that would affect investor assessment of the company's pipeline and technology platform.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-23T10:04:22.479606+00:00","company_name":"Evaxion A/S","ticker":"EVAX","filing_date":"2026-10-23"}]}